This study looks at a medicine called barzolvolimab for adults with Chronic Spontaneous Urticaria (CSU). CSU is a skin condition that causes itchy hives for no clear reason. The study follows people who finished earlier tests to see how well the medicine works and if it is safe over a long time.
The study has two groups:
- Group 1: People with lower UAS7 scores (under 16) will be watched for about 52 weeks. UAS7 is a score that measures the severity of hives.
- Group 2: People with higher UAS7 scores (16 or above) will get the medicine for around 68 weeks.
To join, you must have already completed previous studies and follow certain rules like using effective birth control if needed. You can't join if you have other itchy skin conditions or certain health issues.
- Length: Group 1 lasts about 52 weeks (longer if medicine is needed), Group 2 lasts up to 68 weeks.
- Participation requires regular updates in an electronic diary.
- Participants will not receive any compensation for joining the study.
How understandable was the trial content above?
Hard to understand
Easy to understand